Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Binimetinib in Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
NCT04322383Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2021
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of binimetinib in hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-V), sponsored by National Cancer Institute. Started Jan 2021; status: recruiting.
02
Drugs
binimetinib
03
Conditions
hairy cell leukemia (HCL)Hairy cell leukemia variant (HCL-V)
Beyond the preview
Go deeper on NCT04322383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04322383.